Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook
185 Views03 Feb 2022 09:00
We analyzed the impact and outlook of growth hormone VBP that led to share price plunge of Anke and CCHT. We also analyzed the bidding strategy for both companies,but the price system would be broken.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?10 Feb 2022
- Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry09 Feb 2022
- Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook08 Feb 2022
- Anke Biotechnology (300009CH) Vs Changchun High & New Tech (000661CH)-Growth Hormone VBP and Outlook03 Feb 2022
- China Healthcare Weekly (Jan.21)-Growth Hormone VBP,Biotech Survival,Internationalization Conditions23 Jan 2022
- Changchun High & New Tech (000661.CH) - Logic Change?16 Aug 2021
- Changchun High & New Tech (000661.CH) - Insights on Recent Pullback & The Future Business Outlook27 May 2021
x